Design, synthesis, and biological evaluation of caprolactam-modified bengamide analogues.
Liu
Gang
G
Chinese National Center for Drug Screening, Shanghai Institute of Materia Medica, 189 Guo Shou Jing Road, Shanghai 201203, China.
Ma
Yi-Ming
YM
Tai
Wan-Yi
WY
Xie
Chuan-Ming
CM
Li
Yu-Lin
YL
Li
Jia
J
Nan
Fa-Jun
FJ
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D001381:Azepines; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002209:Caprolactam / Q000138:chemical synthesis / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D020128:Inhibitory Concentration 50; D012995:Solubility; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology; D014867:Water / Q000737:chemistry
C438868:3,4,5-trihydroxy-2--methoxy-8,8-dimethyl-N-(hexahydro-2-oxo-6-(cyclohexylcarbonyl)oxy-2H-azepin-3-yl)non-6-enamide; D000970:Antineoplastic Agents; D001381:Azepines; D014867:Water; C427480:bengamide B; D002209:Caprolactam